JP2011520915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520915A5 JP2011520915A5 JP2011509762A JP2011509762A JP2011520915A5 JP 2011520915 A5 JP2011520915 A5 JP 2011520915A5 JP 2011509762 A JP2011509762 A JP 2011509762A JP 2011509762 A JP2011509762 A JP 2011509762A JP 2011520915 A5 JP2011520915 A5 JP 2011520915A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pyran
- tetrahydro
- cyclopropylsulfonyl
- propanamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 aryl (C 1-10 ) alkyl Chemical group 0.000 claims description 283
- 150000001875 compounds Chemical class 0.000 claims description 35
- HAMZIZRSAJARRH-UHFFFAOYSA-N 4-cyclopropylsulfonyl-1-[1-[(5-fluoro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]indazole-6-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC(S(=O)(=O)C3CC3)=C2C=NN1C(C(=O)NC=1SC(F)=CN=1)CC1CCOCC1 HAMZIZRSAJARRH-UHFFFAOYSA-N 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 132
- 125000005842 heteroatom Chemical group 0.000 claims 102
- 125000000753 cycloalkyl group Chemical group 0.000 claims 60
- 125000003118 aryl group Chemical group 0.000 claims 38
- 150000001602 bicycloalkyls Chemical group 0.000 claims 29
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 25
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 25
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000004104 aryloxy group Chemical group 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 21
- 125000001072 heteroaryl group Chemical group 0.000 claims 20
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 17
- 125000003282 alkyl amino group Chemical group 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 16
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 12
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 11
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 11
- 238000004519 manufacturing process Methods 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 9
- 229940124530 sulfonamide Drugs 0.000 claims 9
- 150000003456 sulfonamides Chemical class 0.000 claims 9
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 8
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 8
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 7
- 150000001408 amides Chemical class 0.000 claims 7
- 125000005188 oxoalkyl group Chemical group 0.000 claims 7
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 7
- 125000005144 cycloalkylsulfonyl group Chemical group 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- KUFXUEYIWPFSHN-HNNXBMFYSA-N (2s)-2-(4-cyclopropylsulfonylpyrazolo[3,4-c]pyridin-1-yl)-n-(5-fluoro-1,3-thiazol-2-yl)-3-(oxan-4-yl)propanamide Chemical compound S1C(F)=CN=C1NC(=O)[C@@H](N1C2=CN=CC(=C2C=N1)S(=O)(=O)C1CC1)CC1CCOCC1 KUFXUEYIWPFSHN-HNNXBMFYSA-N 0.000 claims 1
- QAVCBIQSDBRVDD-UHFFFAOYSA-N 4-chloro-1-[1-[(5-chloro-1,3-thiazol-2-yl)amino]-3-(oxan-4-yl)-1-oxopropan-2-yl]-n-cyclopropylpyrazole-3-carboxamide Chemical compound S1C(Cl)=CN=C1NC(=O)C(N1N=C(C(Cl)=C1)C(=O)NC1CC1)CC1CCOCC1 QAVCBIQSDBRVDD-UHFFFAOYSA-N 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 125000004536 indazol-1-yl group Chemical group N1(N=CC2=CC=CC=C12)* 0.000 claims 1
- 208000011661 metabolic syndrome X Diseases 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- NPMMXKUVLURCMA-UHFFFAOYSA-N n-(oxan-4-yl)propanamide Chemical compound CCC(=O)NC1CCOCC1 NPMMXKUVLURCMA-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5405208P | 2008-05-16 | 2008-05-16 | |
| US61/054,052 | 2008-05-16 | ||
| US10837008P | 2008-10-24 | 2008-10-24 | |
| US61/108,370 | 2008-10-24 | ||
| PCT/US2009/044190 WO2009140624A2 (en) | 2008-05-16 | 2009-05-15 | Glucokinase activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520915A JP2011520915A (ja) | 2011-07-21 |
| JP2011520915A5 true JP2011520915A5 (https=) | 2012-07-12 |
| JP5513492B2 JP5513492B2 (ja) | 2014-06-04 |
Family
ID=41076813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509762A Expired - Fee Related JP5513492B2 (ja) | 2008-05-16 | 2009-05-15 | グルコキナーゼ活性剤 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US8563730B2 (https=) |
| EP (1) | EP2294053B1 (https=) |
| JP (1) | JP5513492B2 (https=) |
| KR (1) | KR20110018366A (https=) |
| CN (1) | CN102105451B (https=) |
| AR (1) | AR071811A1 (https=) |
| AU (1) | AU2009246167B2 (https=) |
| BR (1) | BRPI0912802A2 (https=) |
| CA (1) | CA2724116A1 (https=) |
| CL (1) | CL2009001203A1 (https=) |
| CO (1) | CO6321274A2 (https=) |
| CR (1) | CR11827A (https=) |
| DO (1) | DOP2010000351A (https=) |
| EA (1) | EA018988B1 (https=) |
| EC (1) | ECSP10010688A (https=) |
| GE (1) | GEP20135783B (https=) |
| IL (1) | IL209062A (https=) |
| MA (1) | MA32391B1 (https=) |
| MX (1) | MX2010012298A (https=) |
| MY (1) | MY152749A (https=) |
| NZ (1) | NZ589084A (https=) |
| PE (2) | PE20141375A1 (https=) |
| SG (1) | SG190625A1 (https=) |
| TW (1) | TWI445707B (https=) |
| UY (1) | UY31830A (https=) |
| WO (1) | WO2009140624A2 (https=) |
| ZA (1) | ZA201007975B (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642597B2 (en) * | 2007-08-27 | 2014-02-04 | Basf Se | Pyrazole compounds for controlling invertebrate pests |
| US20100330177A1 (en) * | 2008-02-05 | 2010-12-30 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| RS52872B (sr) | 2008-08-27 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Jedinjenja pirola |
| KR101258331B1 (ko) * | 2008-09-11 | 2013-04-26 | 화이자 인코포레이티드 | 헤테로아릴 아미드 유도체 및 글루코키나제 활성화제로서의 그의 용도 |
| PL2342196T3 (pl) * | 2008-09-24 | 2015-12-31 | Basf Se | Związki pirazolowe do zwalczania szkodników będących bezkręgowcami |
| WO2011003796A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| WO2011003793A1 (en) | 2009-07-06 | 2011-01-13 | Basf Se | Pyridazine compounds for controlling invertebrate pests |
| WO2011009804A2 (en) | 2009-07-24 | 2011-01-27 | Basf Se | Pyridine derivatives compounds for controlling invertebrate pests |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2800498C (en) | 2010-03-31 | 2021-11-16 | The Scripps Research Institute | Reprogramming cells |
| PT2576524T (pt) * | 2010-05-26 | 2017-11-17 | Vtv Therapeutics Llc | Resumo |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| JP2013544787A (ja) * | 2010-10-13 | 2013-12-19 | タケダ カリフォルニア インコーポレイテッド | アザインダゾール誘導体の調製方法 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1202458A1 (en) | 2012-05-17 | 2015-10-02 | Vtv治疗有限责任公司 | Glucokinase activator compositions for the treatment of diabetes |
| HK1213780A1 (zh) * | 2013-03-04 | 2016-07-15 | Vtv治疗有限责任公司 | 穩定的葡萄糖激酶活化劑組合物 |
| EP2878339A1 (en) | 2013-12-02 | 2015-06-03 | Siena Biotech S.p.A. | SIP3 antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| EP3372585B1 (en) * | 2014-12-19 | 2022-03-30 | Aragon Pharmaceuticals, Inc. | Process for the preparation of a diarylthiohydantoin compound |
| CN105092770B (zh) * | 2015-01-12 | 2017-03-29 | 上海中医药大学 | 一种筛选二肽基肽酶四抑制剂的方法 |
| WO2016202688A1 (en) | 2015-06-15 | 2016-12-22 | Bayer Cropscience Aktiengesellschaft | Halogen-substituted phenoxyphenylamidines and the use thereof as fungicides |
| MX2017016363A (es) | 2015-06-15 | 2018-03-02 | Bayer Cropscience Ag | Fenoxifenilamidinas sustituidas con halogeno y el uso de estas como fungicidas. |
| EP3335559A1 (en) | 2016-12-14 | 2018-06-20 | Bayer CropScience Aktiengesellschaft | Active compound combinations |
| WO2018109002A1 (en) | 2016-12-14 | 2018-06-21 | Bayer Cropscience Aktiengesellschaft | Active compound combinations |
| GB201714777D0 (en) | 2017-09-14 | 2017-11-01 | Univ London Queen Mary | Agent |
| SG11202011883RA (en) * | 2018-05-31 | 2020-12-30 | Hua Medicine Shanghai Ltd | Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof |
| CN112040945A (zh) | 2018-06-12 | 2020-12-04 | Vtv治疗有限责任公司 | 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途 |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3181722A1 (en) | 2020-06-08 | 2021-12-16 | Jing TENG | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE910278A1 (en) | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
| US5612360A (en) * | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| GB9315846D0 (en) | 1993-07-30 | 1993-09-15 | Isis Innovation | Tumour inhibitors |
| US5795726A (en) | 1996-11-12 | 1998-08-18 | Millennium Pharmaceuticals, Inc. | Methods for identifying compounds useful in treating type II diabetes |
| GB9806692D0 (en) * | 1998-03-27 | 1998-05-27 | Pharmacia & Upjohn Spa | Benzoheterocyclic distamycin derivatives, process for preparing them and their use as antitumour agents |
| SI1169312T1 (en) | 1999-03-29 | 2005-02-28 | F. Hoffmann-La Roche Ag | Glucokinase activators |
| US20030013633A1 (en) * | 1999-06-07 | 2003-01-16 | Rima Kaddurah-Daouk | Use of molecules that modulate an energy related associated state |
| US6353111B1 (en) | 1999-12-15 | 2002-03-05 | Hoffmann-La Roche Inc. | Trans olefinic glucokinase activators |
| CA2393083C (en) | 1999-12-23 | 2010-01-26 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
| AU2001252270B2 (en) | 2000-05-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Hydantoin-containing glucokinase activators |
| KR100519826B1 (ko) | 2000-05-08 | 2005-10-06 | 에프. 호프만-라 로슈 아게 | 파라-아민 치환된 페닐아미드 글루코키나제 활성화제 |
| MXPA03000365A (es) | 2000-07-20 | 2003-05-27 | Hoffmann La Roche | Bencenacetamida substituida con alfa-acilo y alfa-heteroatomo como activadores de la glucocinasa. |
| US6433188B1 (en) * | 2000-12-06 | 2002-08-13 | Wendy Lea Corbett | Fused heteroaromatic glucokinase activators |
| US6482951B2 (en) | 2000-12-13 | 2002-11-19 | Hoffmann-La Roche Inc. | Isoindolin-1-one glucokinase activators |
| WO2003002062A2 (en) | 2001-06-29 | 2003-01-09 | Tularik Inc. | Bis-aryl thiazole derivatives |
| AU2002349299A1 (en) | 2001-12-03 | 2003-06-17 | Novo Nordisk A/S | Use of a glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
| WO2003055482A1 (en) | 2001-12-21 | 2003-07-10 | Novo Nordisk A/S | Amide derivatives as gk activators |
| WO2003080585A1 (en) | 2002-03-26 | 2003-10-02 | Banyu Pharmaceutical Co., Ltd. | Novel aminobenzamide derivative |
| WO2004026226A2 (en) | 2002-05-10 | 2004-04-01 | Cytokinetics, Inc. | Compounds, compositions and methods |
| BR0312023A (pt) | 2002-06-27 | 2005-03-22 | Novo Nordisk As | Composto, composto ativador da glicose cinase, método para evitar a hipoglicemia, uso de um composto, e, composição farmacêutica |
| GB0216097D0 (en) | 2002-07-11 | 2002-08-21 | Univ London | Treatment of proliferative disorders |
| US20040156826A1 (en) | 2002-09-27 | 2004-08-12 | Fernando Dangond | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| BR0314864A (pt) | 2002-10-03 | 2005-08-02 | Novartis Ag | Compostos orgânicos |
| RU2309956C2 (ru) * | 2002-10-03 | 2007-11-10 | Ф.Хоффманн-Ля Рош Аг | Производные индол-3-карбоксамида в качестве активаторов глюкокиназы |
| EP1556088A2 (en) | 2002-10-29 | 2005-07-27 | Engene, Inc. | Compositions for cancer treatment |
| DE60336850D1 (en) | 2003-01-06 | 2011-06-01 | Lilly Co Eli | Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren |
| WO2004072066A1 (en) | 2003-02-11 | 2004-08-26 | Prosidion Limited | Tri(cyclo) substituted amide glucokinase activator compounds |
| PL378117A1 (pl) | 2003-02-11 | 2006-03-06 | Prosidion Limited | Tricyklopodstawione związki amidowe |
| US7179613B2 (en) * | 2003-05-05 | 2007-02-20 | Vanderbilt University | Methods of screening for a candidate modulator of glucokinase |
| GB0325402D0 (en) * | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| WO2005052132A2 (en) | 2003-11-24 | 2005-06-09 | Exelixis, Inc | Mbms as modifiers of branching morphogenesis and methods of use |
| GB0328178D0 (en) * | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| US7750020B2 (en) | 2004-04-02 | 2010-07-06 | Novartis Ag | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of Type 2 diabetes |
| CA2563192A1 (en) | 2004-04-21 | 2005-11-03 | Prosidion Limited | Tri(cyclo) substituted amide compounds |
| JP2008502658A (ja) | 2004-06-17 | 2008-01-31 | ノボ ノルディスク アクティーゼルスカブ | 肝臓選択的グルコキナーゼ活性化因子の使用 |
| WO2006002121A2 (en) | 2004-06-17 | 2006-01-05 | Wisconsin Alumni Research Foundation | Compounds and methods for treating seizure and paroxysmal disorders |
| GB0418058D0 (en) | 2004-08-12 | 2004-09-15 | Prosidion Ltd | Fluorination process |
| AU2005271016A1 (en) | 2004-08-12 | 2006-02-16 | Prosidion Limited | Substituted phenylacetamides and their use as glucokinase activators |
| WO2006024490A2 (en) | 2004-08-30 | 2006-03-09 | Interstitial Therapeutics | Methods and compositions for the treatment of cell proliferation |
| EP1891971A4 (en) | 2005-01-31 | 2010-02-03 | Ajinomoto Kk | MEDICAL COMPOSITION USING HYPERGLY CRAB MEDICAMENT TO TREAT OR TREAT GLUCOSE-INTOLERANCE, BORDERLINE DIABETES, INSULIN RESISTANCE AND HYPERINSULINEMIA |
| JP2009501513A (ja) | 2005-06-22 | 2009-01-22 | メルク エンド カムパニー インコーポレーテッド | Ｈｃｖ複製阻害の標的 |
| US7565029B2 (en) * | 2005-07-08 | 2009-07-21 | Seiko Epson Corporation | Method for determining camera position from two-dimensional images that form a panorama |
| WO2007007886A1 (en) | 2005-07-11 | 2007-01-18 | Mitsubishi Tanabe Pharma Corporation | An oxime derivative and preparations thereof |
| CA2621227A1 (en) | 2005-08-31 | 2007-03-08 | Astellas Pharma Inc. | Thiazole derivative |
| GT200600429A (es) | 2005-09-30 | 2007-04-30 | Compuestos organicos | |
| WO2007051846A1 (en) * | 2005-11-03 | 2007-05-10 | Prosidion Ltd | Tricyclo substituted amides |
| US20080293741A1 (en) | 2005-11-03 | 2008-11-27 | Matthew Colin Thor Fyfe | Tricyclo Substituted Amides as Glucokinase Modulators |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| JP2009520825A (ja) * | 2005-12-20 | 2009-05-28 | 武田薬品工業株式会社 | グルコキナーゼ活性剤 |
| US8034822B2 (en) * | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2007115968A2 (en) | 2006-04-12 | 2007-10-18 | F. Hoffmann-La Roche Ag | Process for the preparation of a glucokinase activator |
| JP5190448B2 (ja) | 2006-04-20 | 2013-04-24 | ファイザー・プロダクツ・インク | グルコキナーゼ仲介疾患を予防および治療するための縮合フェニルアミド複素環化合物 |
| US7842713B2 (en) * | 2006-04-20 | 2010-11-30 | Pfizer Inc | Fused phenyl amido heterocyclic compounds |
| EP2049518B1 (en) * | 2006-05-31 | 2011-08-31 | Takeda San Diego, Inc. | Indazole and isoindole derivatives as glucokinase activating agents. |
| US7910747B2 (en) | 2006-07-06 | 2011-03-22 | Bristol-Myers Squibb Company | Phosphonate and phosphinate pyrazolylamide glucokinase activators |
| US8163779B2 (en) * | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| US8173645B2 (en) * | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| US20100183514A1 (en) | 2007-05-29 | 2010-07-22 | President And Fellows Of Harvard College | Molecules involved in regulation of osteoblast activity and osteoclast activity, and methods of use thereof |
| WO2009022179A2 (en) | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| BRPI0912802A2 (pt) | 2008-05-16 | 2015-10-13 | Takeda San Diego Inc | ativadores de glicoquinase |
| JP2013522294A (ja) | 2010-03-18 | 2013-06-13 | タケダ カリフォルニア インコーポレイテッド | ２−アミノ−５−フルオロチアゾールの製造プロセス |
| JP2013544787A (ja) | 2010-10-13 | 2013-12-19 | タケダ カリフォルニア インコーポレイテッド | アザインダゾール誘導体の調製方法 |
-
2009
- 2009-05-15 BR BRPI0912802A patent/BRPI0912802A2/pt not_active IP Right Cessation
- 2009-05-15 TW TW98116300A patent/TWI445707B/zh not_active IP Right Cessation
- 2009-05-15 PE PE2014000756A patent/PE20141375A1/es not_active Application Discontinuation
- 2009-05-15 AU AU2009246167A patent/AU2009246167B2/en not_active Ceased
- 2009-05-15 MY MYPI20105245 patent/MY152749A/en unknown
- 2009-05-15 EP EP09747705.3A patent/EP2294053B1/en not_active Not-in-force
- 2009-05-15 PE PE2009000690A patent/PE20091901A1/es not_active Application Discontinuation
- 2009-05-15 GE GEAP2009012029 patent/GEP20135783B/en unknown
- 2009-05-15 CN CN2009801273588A patent/CN102105451B/zh not_active Expired - Fee Related
- 2009-05-15 SG SG2013034012A patent/SG190625A1/en unknown
- 2009-05-15 EA EA201071320A patent/EA018988B1/ru not_active IP Right Cessation
- 2009-05-15 MX MX2010012298A patent/MX2010012298A/es active IP Right Grant
- 2009-05-15 WO PCT/US2009/044190 patent/WO2009140624A2/en not_active Ceased
- 2009-05-15 US US12/467,041 patent/US8563730B2/en not_active Expired - Fee Related
- 2009-05-15 UY UY31830A patent/UY31830A/es not_active Application Discontinuation
- 2009-05-15 NZ NZ589084A patent/NZ589084A/en not_active IP Right Cessation
- 2009-05-15 CL CL2009001203A patent/CL2009001203A1/es unknown
- 2009-05-15 CA CA 2724116 patent/CA2724116A1/en not_active Abandoned
- 2009-05-15 AR ARP090101763 patent/AR071811A1/es unknown
- 2009-05-15 JP JP2011509762A patent/JP5513492B2/ja not_active Expired - Fee Related
- 2009-05-15 KR KR20107028256A patent/KR20110018366A/ko not_active Ceased
-
2010
- 2010-11-01 IL IL209062A patent/IL209062A/en not_active IP Right Cessation
- 2010-11-08 ZA ZA2010/07975A patent/ZA201007975B/en unknown
- 2010-11-15 DO DO2010000351A patent/DOP2010000351A/es unknown
- 2010-12-07 CO CO10154094A patent/CO6321274A2/es not_active Application Discontinuation
- 2010-12-07 CR CR11827A patent/CR11827A/es unknown
- 2010-12-10 MA MA33420A patent/MA32391B1/fr unknown
- 2010-12-16 EC ECSP10010688 patent/ECSP10010688A/es unknown
-
2012
- 2012-04-10 US US13/443,774 patent/US20120225887A1/en not_active Abandoned
-
2013
- 2013-10-02 US US14/044,687 patent/US9139598B2/en not_active Expired - Fee Related
-
2015
- 2015-09-21 US US14/860,573 patent/US20160009735A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520915A5 (https=) | ||
| US10577367B2 (en) | IRAK4 inhibiting agents | |
| US9790210B2 (en) | N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors | |
| CA2835835C (en) | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors | |
| EP2549875B1 (en) | Soluble guanylate cyclase activators | |
| JP6109192B2 (ja) | ピリダジンアミド化合物及びｓｙｋ阻害剤としてのそれらの使用 | |
| AU2002341921B8 (en) | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| JP5878178B2 (ja) | １，２，４−トリアジン−６−カルボキサミド誘導体 | |
| EP1835934A2 (en) | Enzyme modulators and treatments | |
| SI2933252T1 (en) | Kinase inhibitors as apoptotic signal regulators | |
| RU2018123779A (ru) | Новые соединения | |
| US11173145B2 (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase | |
| US8455507B2 (en) | Aminopyrimidines useful as kinase inhibitors | |
| ME02100B (me) | Derivati 4-aminopirimidina i njihova primena kao antagonista adenozinskog a2a receptora | |
| AU2006315334A1 (en) | Aminopyrimidines useful as kinase inhibitors | |
| WO2014026327A1 (en) | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof | |
| TW201202221A (en) | Nitrogen containing heteroaryl compounds | |
| JP2014521651A (ja) | 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 | |
| MX2008015648A (es) | Pirazinonas como inhibidores de proliferacion celular. | |
| TW200817375A (en) | Compounds and compositions as ITPKB inhibitors | |
| JP2018506571A (ja) | Ｒｈｏ関連プロテインキナーゼの阻害及び疾患の治療のためのインダゾリルチアジアゾールアミン及び関連する化合物 | |
| TW200526641A (en) | Amidopyrazole derivatives | |
| JP6176244B2 (ja) | 芳香族複素環誘導体及び医薬 | |
| EP4565575A1 (en) | Kit inhibitors, compounds, pharmaceutical compositions, and methods of use thereof | |
| JP2006045118A (ja) | 新規ピラゾロキノロン誘導体 |